Ph 2 Elacestrant in ER Positive Uterine Sarcomas

NCT07467772 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Uterine Sarcoma
Uterine Leiomyosarcoma
Endometrial Stromal Sarcoma
ESS
Perivascular Epithelioid Cell Tumors
Uterine Adenosarcoma
Uterine PEComa
Estrogen Receptor Positive Tumor
uLMS

Interventions

DRUG: Elacestrant

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]